Oncological outcome after MRI‐based selection for neoadjuvant chemoradiotherapy in the OCUM Rectal Cancer Trial. BJS 2018; 105: 1519-1529.
Published: 9th May 2018
Authors: R. Ruppert, T. Junginger, H. Ptok, J. Strassburg, C. A. Maurer, P. Brosi et al.
It is not clear whether all patients with rectal cancer need chemoradiotherapy. A restrictive use of neoadjuvant chemoradiotherapy (nCRT) based on MRI findings for rectal cancer was investigated in this study.
This prospective multicentre observational study included patients with stage cT2–4 rectal cancer, with any cN and cM0 status. Carcinomas in the middle and lower third that were 1 mm or less from the mesorectal fascia, all cT4 tumours, and all cT3 tumours of the lower third were classified as high risk, and these patients received nCRT followed by total mesorectal excision (TME). All other carcinomas with a minimum distance of more than 1 mm from the mesorectal fascia and those in the upper third were classified as low risk; these patients underwent TME alone (no nCRT). Patients were followed for at least 3 years. Outcomes were the rates of local recurrence, distant metastasis and survival.
Among 545 patients included, 428 were treated according to the study protocol: 254 (59·3 per cent) had TME alone and 174 (40·7 per cent) received nCRT and TME. Median follow‐up was 60 months. The 3‐ and 5‐year local recurrence rates were 1·3 and 2·7 per cent respectively, with no differences between the two treatment protocols. Patients with disease requiring nCRT had higher 3‐ and 5‐year rates of distant metastasis (17·3 and 24·9 per cent respectively
Restriction of nCRT to high‐risk patients achieved good results.Full text
You may also be interested in
Authors: H. Elfeki, H. M. Larsen, K. J. Emmertsen, P. Christensen, M. Youssef, W. Khafagy et al.
Notes: Sigmoid resection associated with bowel dysfunction
Authors: J. Segelman, C. Buchli, A. Svanström Röjvall, P. Matthiessen, S. Arver, M. Bottai et al.
Notes: Ovarian androgens reduced
Randomized clinical trial
Randomized clinical trial of short or long interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer. BJS 2018; 105: 1417-1425.
Authors: E. Akgun, C. Caliskan, O. Bozbiyik, T. Yoldas, M. Sezak, S. Ozkok et al.
Notes: Worth waiting
Authors: M. Baré, L. Mora, N. Torà, M. J. Gil, I. Barrio, P. Collera et al.
Notes: Defines risk
Authors: M. Ishimaru, H. Matsui, S. Ono, Y. Hagiwara, K. Morita, H. Yasunaga et al.
Notes: Preoperative dental care reduces postoperative pneumonia
Prognostic implications of MRI‐detected lateral nodal disease and extramural vascular invasion in rectal cancer.
Authors: D. P. Schaap, A. Ogura, J. Nederend, M. Maas, J. S. Cnossen, G. J. Creemers et al.
Notes: Defines recurrence risk
Multicentre international trial of laparoscopic lavage for Hinchey III acute diverticulitis (LLO Study).
Authors: G. A. Binda, M. A. Bonino, G. Siri, S. Di Saverio, G. Rossi, R. Nascimbeni et al.
Notes: Successful in the majority
Authors: M. R. Weiser, M. Gonen, S. Usiak, T. Pottinger, P. Samedy, D. Patel et al.
Notes: Protocol‐driven programme works
Meta‐analysis of in‐hospital delay before surgery as a risk factor for complications in patients with acute appendicitis. BJS 2018; 105: 933-945.
Authors: S. T. van Dijk, A. H. van Dijk, M. G. Dijkgraaf, M. A. Boermeester
Notes: Delay is safe
Magnetic resonance tumour regression grade and pathological correlates in patients with rectal cancer.
Authors: J. K. Jang, J. L. Lee, S. H. Park, H. J. Park, I. J. Park, J. H. Kim et al.
Long‐term prognostic impact of surgical complications in the German Rectal Cancer Trial CAO/ARO/AIO‐94. BJS 2018; 105: 1510-1518.
Authors: T. Sprenger, T. Beißbarth, R. Sauer, J. Tschmelitsch, R. Fietkau, T. Liersch et al.
Notes: Morbidity matters